RECRUITING

Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet. This 6-month study will have 2 phases: a 12-week controlled feeding phase and a 12-week "free living" phase. During the controlled feeding phase, all food will be provided to the families of the participants for the entirety of the 12 weeks. Participants (n=80) will have been diagnosed with NAFLD based on the presence of current evidence of active disease, which will be determined by the ongoing presence of hepatic steatosis estimated by diffusely echogenic liver via ultrasound suggestive of fatty liver and a serum alanine aminotransferase (ALT) level of 45 U/L or greater. All participants will be children and adolescents age 10-17 yrs.; will have an HbA1c \<7.0; and will be overweight or obese (BMI \>85th percentile). It is anticipated that most participants will be sedentary. The investigators will inquire as to routine physical activity at screening. All participants will be asked to maintain their usual level of physical activity throughout the study. Physical activity will be monitored via a smart watch provided to each participant at the beginning of the study, and participants will be queried weekly by the study dietitian regarding changes in physical activity. Participants who use oral contraceptives will be asked to maintain consistent use of these preparations throughout the study. Hormone use will be examined as a potential covariate in statistical analyses.

Official Title

Moderately Carbohydrate-restricted Diet as Treatment Targeting Improvement in Hepatic Lipid and Insulin Sensitivity in Adolescents With NAFLD

Quick Facts

Study Start:2022-05-01
Study Completion:2026-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05268042

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:10 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * clinical-pathological diagnosis of NAFLD and current evidence of active disease, which will be determined by the ongoing presence of hepatic steatosis estimated by diffusely echogenic liver via ultrasound suggestive of fatty liver and a serum alanine aminotransferase (ALT) level of 45 U/L or greater.
  2. * age 10 -17 yrs
  3. * overweight or obese (BMI \>75th percentile).
  1. * pregnancy
  2. * HbA1c \>7%
  3. * history of parenteral nutrition
  4. * hepatic virus infections (HCV RNA-polymerase chain reaction negative; hepatitis A, B, C, D, E, and G; cytomegalovirus; and Epstein-Barr virus)
  5. * use of medications known to induce steatosis (e.g. valproate, amiodarone, or prednisone), elevate liver enzymes, or affect body weight and carbohydrate metabolism (within the last 6months)
  6. * autoimmune liver disease
  7. * metabolic liver disease
  8. * Wilson's disease
  9. * genetic conditions (e.g. glycogen storage disorder) leading to hepatic steatosis;
  10. * history of bariatric surgery
  11. * participants and parents/guardians unwilling or unable to give informed consent, accept random assignment, attend dietary counseling sessions, adhere to treatment prescription, or complete study measures
  12. * inability to speak and comprehend English (participants and parents/guardians)
  13. * currently receiving intense lifestyle modification treatment
  14. * estimated Glomerular Filtration Rate (eGFR) \<60
  15. * alcohol, tobacco or recreational drug use
  16. * unable to undergo MRI.

Contacts and Locations

Study Contact

Alex Luzuriaga-McPherson
CONTACT
205-934-6299
alexandramcpherson@uabmc.edu

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35226
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-01
Study Completion Date2026-03-31

Study Record Updates

Study Start Date2022-05-01
Study Completion Date2026-03-31

Terms related to this study

Keywords Provided by Researchers

  • NAFLD
  • Obesity
  • Insulin sensitivity

Additional Relevant MeSH Terms

  • Non-Alcoholic Fatty Liver Disease
  • Obesity